Skip to main content

Nuvectis Pharma, Inc.

corporate_fare Company Profile

Nuvectis Pharma, Inc.

NVCT·NASDAQ·Life Sciences·CIK 0001875558

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company that develops innovative precision medicines for serious, unmet medical needs in oncology. The company focuses on creating drug candidates in the precision medicine field, basing its selection and clinical development processes on scientific data regarding cancer-promoting factors, clinical landscape understanding, and regulatory requirements. Nuvectis Pharma, Inc. was incorporated in July 2020 in Delaware as Centry Pharma, Inc., changing its name in July 2021. Its office is located at 1 Bridge Plaza, 2nd Floor, Fort Lee, NJ 07024. The company's primary product under development is NXP900. In August 2021, Nuvectis Pharma licensed worldwide commercial rights for NXP900 from the University of Edinburgh in Scotland. NXP900 is a targeted-therapy, small molecule drug candidate designed to inhibit the proto-oncogene c-Src ("SRC") and YES1 kinases, which are key members of the SRC kinase family. In May 2023, the U.S. Food and Drug Administration ("FDA") cleared the Investigational New Drug application ("IND") for NXP900, which included a Phase 1 protocol consisting of a dose-escalation Phase 1a and an expansion Phase 1b.

Nuvectis Pharma, Inc. (NASDAQ:NVCT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for NVCT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for NVCT spans 10-Q, S-3, 8-K, 4.

Recent high-impact activity:

  • Nuvectis Halts NXP800 in Ovarian Cancer as Q3 Loss Widens to $30.1M
  • Nuvectis Q3 10-Q: $140.7M Cash, $43.1M Nine-Month Loss After Haisco Charge
  • Cash Swells to $140.7M With Runway to 2H 2029 as Dual INDs Target Year-End
  • NXP200 Delivers 40% ORR and Complete Responses in Recurrent Glioma at ESMO
  • NXP200 Wins Breakthrough Therapy Designation in China for High-Grade Glioma

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$26.44M
Diluted EPS
-$1.32
Op. Cash Flow
-$16.01M
Operating Income
-$27.57M
Cash & Equivalents
$31.63M
Debt / Equity
0.00×
Shares Outstanding
25.68M sh
Source: 10-K · filed 2026-02-11 · accession 0001104659-26-013044

Short Interest & Short Volume

15.16 days to cover

FINRA reported short interest of 2,544,952 shares in NVCT as of the October 30, 2026 settlement, a 6.0% increase from the prior period — about 15.2 days to cover at its recent average daily volume. On November 20, 2026, 62.3% of NVCT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,544,952 shares as of October 30, 2026
Change vs prior period▲ 6.0%
Days to cover15.16 at avg daily volume of 167,866
Daily short volume (FINRA facilities)62.3% of 107,521 shares on November 20, 2026
5-day average short volume74.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for NVCT, detected from its recent SEC filings · based on capital-structure filings through 2026-08-21.

1 recent capital raiseATM program1 shelf registration

Public Offering Priced · Significant Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with N →
$20.4 +2.82% today
52-week range · as of 2026-11-04 $5.55 – $29.27
Market cap
$666.8M
Volume
301.6K (1.5× avg)
3-mo avg 205.1K
Live data · 2026-11-22 03:13 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NVCT - Latest Insights

NVCT
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $19.42
Real-time Price: $20.40 info
Change: +$0.980 (+5%) info
Market Cap: $666.801M info
NVCT
Nov 04, 2026, 8:07 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $19.34
Real-time Price: $20.40 info
Change: +$1.06 (+5%) info
Market Cap: $666.801M info
NVCT
Nov 04, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $19.34
Real-time Price: $20.40 info
Change: +$1.06 (+5%) info
Market Cap: $666.801M info
NVCT
Oct 26, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $20.05
Real-time Price: $20.40 info
Change: +$0.350 (+2%) info
Market Cap: $666.801M info
NVCT
Sep 24, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $21.70
Real-time Price: $20.40 info
Change: -$1.30 (-6%) info
Market Cap: $666.801M info
NVCT
Aug 21, 2026, 4:37 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $23.56
Real-time Price: $20.40 info
Change: -$3.16 (-13%) info
Market Cap: $666.801M info
NVCT
Aug 04, 2026, 9:01 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $18.50
Real-time Price: $20.40 info
Change: +$1.90 (+10%) info
Market Cap: $666.801M info
NVCT
Aug 04, 2026, 8:25 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $21.40
Real-time Price: $20.40 info
Change: -$1.00 (-5%) info
Market Cap: $666.801M info
NVCT
Aug 04, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $21.52
Real-time Price: $20.40 info
Change: -$1.12 (-5%) info
Market Cap: $666.801M info
NVCT
Jul 23, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $19.29
Real-time Price: $20.40 info
Change: +$1.11 (+6%) info
Market Cap: $666.801M info
NVCT
Jul 01, 2026, 1:39 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $19.02
Real-time Price: $20.40 info
Change: +$1.38 (+7%) info
Market Cap: $666.801M info
NVCT
Jun 30, 2026, 4:43 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $18.78
Real-time Price: $20.40 info
Change: +$1.62 (+9%) info
Market Cap: $666.801M info
NVCT
Jun 30, 2026, 4:41 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $18.99
Real-time Price: $20.40 info
Change: +$1.41 (+7%) info
Market Cap: $666.801M info
NVCT
Jun 30, 2026, 11:26 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $18.76
Real-time Price: $20.40 info
Change: +$1.64 (+9%) info
Market Cap: $666.801M info
NVCT
Jun 29, 2026, 10:30 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $23.12
Real-time Price: $20.40 info
Change: -$2.72 (-12%) info
Market Cap: $666.801M info
NVCT
Jun 29, 2026, 4:31 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $22.97
Real-time Price: $20.40 info
Change: -$2.57 (-11%) info
Market Cap: $666.801M info
NVCT
Jun 29, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $28.13
Real-time Price: $20.40 info
Change: -$7.73 (-27%) info
Market Cap: $666.801M info
NVCT
Jun 29, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $28.14
Real-time Price: $20.40 info
Change: -$7.74 (-28%) info
Market Cap: $666.801M info
NVCT
Jun 23, 2026, 7:03 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $16.25
Real-time Price: $20.40 info
Change: +$4.15 (+26%) info
Market Cap: $666.801M info
NVCT
Jun 23, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $16.25
Real-time Price: $20.40 info
Change: +$4.15 (+26%) info
Market Cap: $666.801M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets